Intracellular expression of antisense RNA transcripts complementary to the human immunodeficiency virus type-1 vif gene inhibits viral replication in infected T-lymphoblastoid cells

Biochemical and Biophysical Research Communications

Volumn 320, Issue 2, 2004, Pages 544-550

  Barnor, Jacob Samson ^a,d   Miyano Kurosaki, Naoko ^a,b   Yamaguchi, Kazuya ^a   Sakamoto, Atsushi ^a   Ishikawa, Koichi ^c   Inagaki, Yoshio ^e   Yamamoto, Naoki ^c,e   Osei Kwasi, Mubarak ^d   Ofori Adjei, David ^d   Takaku, Hiroshi ^a,b  

^a Dept of Life and Environ Science ^*  (Japan)

^b CHIBA INSTITUTE OF TECHNOLOGY   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d University of Ghana   (Ghana)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Antisense RNA; Gene therapy; HIV 1 vif; Inhibition of HIV 1 replication

Indexed keywords

COMPLEMENTARY RNA; VIF PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; CARCINOMA CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOID CELL; PRIORITY JOURNAL; RNA TRANSCRIPTION; T LYMPHOBLAST; VIRUS GENE; VIRUS INFECTION; VIRUS REPLICATION;

BASE SEQUENCE; CELL LINE; DNA PRIMERS; DOWN-REGULATION; GENES, VIF; HIV-1; HUMANS; RNA, ANTISENSE; RNA, MESSENGER; T-LYMPHOCYTES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 2942735199     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.05.201     Document Type: Article

References (42)

1. Miller R.J., Cairns J.S., Bridges S., Sarver N. Human immunodeficiency virus and AIDS: insights from animal lentiviruses. J. Virol. 74:2000;7187-7195
2. Seroude V., Audoly G., Gluschankof P., Suzan M. Tryptophan 95, an amino acid residue of the Caprine arthritis encephalitis virus vif protein, which is essential for virus replication. Virology. 280:2001;232-242
3. Metharom P., Takyar S., Xia H.Q., Ellem K.A., Wilcot G.E., Wei M.Q. Development of disabled, replication-defective gene transfer vectors from the Jembrana disease virus, a new infectious agent of cattle. Vet. Microbiol. 80:2001;9-22
4. Chatterji U., Grant C.K., Elder J.H. Feline immunodeficiency virus Vif localizes to the nucleus. J. Virol. 74:2000;2533-2540
5. Dettenhofer M., Cen S., Carlson B.A., Kleiman L., Yu X.F. Association of human immunodeficiency virus type-1 Vif with RNA and its role in reverse transcription. J. Virol. 74:2000;8938-8945
6. Goncalves J., Jallepalli P., Gabuzda D.H. Subcellular localization of the Vif protein of human immunodeficiency virus type 1. J. Virol. 70:1994;704-712
7. Goncalves J., Silva F., Freitas-Vieira A., Santa-Marta M., Malho R., Yang X., Gabuzda D., Barbas III C. Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication. J. Biol. Chem. 277:2002;32036-32045
8. Henzler T., Harmache A., Herrman H., Spring H., Suzan M., Audoly G., Panek T., Bosch V. Fully functional, naturally occurring and C-terminally truncated variant human immunodeficiency virus (HIV) Vif does not bind to HIV Gag but influences intermediate filament structure. J. Gen. Virol. 82:2001;561-573
9. Karczewski M.K., Strebel K. Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J. Virol. 70:1996;494-507
10. Simon J.H., Miller D.L., Fouchier R.A., Soares M.A., Peden K.W., Malim M.H. The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission. EMBO J. 17:1998;1259-1267
11. 4+ T lymphocytes. J. Virol. 66:1992;6489-6495
12. Von Schwedler U., Song J., Aiken C., Trono D. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67:1993;4945-4955
13. Sova P., Volsky V. Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J. Virol. 67:1993;6322-6326
14. Fouchier R.A., Simon J.H., Jaffe A.B., Malim M.H. Human immunodeficiency virus type-1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J. Virol. 70:1996;8263-8269
15. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 418:2002;646-650
16. Roberto M., Chen D., Schrofelbauer B., Navarro F., Konig R., Boliman B., Munk C., Nymark-McMahon H., Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 114:2003;21-31
17. Madani N., Millette R., Platt E.J., Marin M., Kozak S.L., Bloch D.B., Kabat D. Implication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1. J. Virol. 76:2002;11133-11138
18. Simon J.H., Gaddis N.C., Fouchier R.A., Malim M.H. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat. Med. 4:1998;1397-1400
19. Simon J.H., Sheehy A.M., Carpenter E.A., Fouchier R.A., Malim M.H. Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J. Virol. 73:1999;2675-2681
20. Bridges S.H., Sarver N. Gene therapy and immune restoration for HIV disease. Lancet. 345:1995;427-475
21. Ojwang J.O., Hampel A., Looney D.J., Wong-Staal F., Rappaport J. Inhibition of human immunodeficiency virus type 1 expression by hairpin ribozyme. Proc. Natl. Acad. Sci. USA. 89:1992;10802-10806
22. Potash M.J., Bentsman G., Muir T., Krachmarov C., Sova P., Volsky D.J. Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif. Proc. Natl. Acad. Sci. USA. 95:1998;13865-13868
23. Mautino M.R., Morgan R.A. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense. Gene Ther. 7:2002;421-431
24. Mautino M.R., Morgan R.A. Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA. Hum Gene Ther. 9:2002;1027-1037
25. Gennari F., Biasolo M.A., Cancellotti E., Radaelli A., De Giuli Morghen C., Bozzoni I., Cereda P.M., Mengoli C., Palu G., Parolin C. Additive and antagonist effects of therapeutic gene combinations for suppression of HIV-1 infection. Antiviral Res. 1:2002;5577-5590
26. Ding S.F., Lombardi R., Nazari R., Joshi S. A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and trans-dominant negative mutant Gag and Env proteins. Front Biosci. 7:2002;15-28
27. ′ leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle Gene Ther. 16:2000;1362-1368
28. Chang H.K., Gendelman R., Lisziewicz J., Gallo R.C., Ensoli B. Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1. Gene Ther. 1:1994;208-216
29. Yu M., Poeschla E., Wong-Staal F. Progress towards gene therapy for HIV infection. Gene Ther. 1:1994;13-26
30. Liu J., Woffendin C., Yang Z.Y., Nabel G.J. Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells. Gene Ther. 1:1994;32-37
31. Sczakiel G., Homann M., Rittner K. Computer-aided search for effective antisense RNA target sequences of the human immunodeficiency virus type 1. Antisense Res. Dev. 3:1993;45-52
32. Biasolo M.A., Radaelli A., del Pup L., Franchin E., De Giuli-Morghen C., Palu G. A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection. J. Virol. 70:1996;2154-2161
33. 4+ lymphocytic cell line expressing antisense and sense RNA molecules containing HIV-1 packaging signal and Rev response element(s). Antisense Res. Dev. 4:1994;19-29
34. Joshi S., Van Brunschot A., Asad S., van der Elst I., Read S.E., Bernstein A. Inhibition of human immunodeficiency virus type 1 multiplication by antisense and sense RNA expression. J. Virol. 65:1991;5524-5530
35. Shahabuddin M., Khan A.S. Inhibition of human immunodeficiency virus type 1 by packageable, multigenic antisense RNA. Antisense Nucleic Acid Drug Dev. 10:2000;141-151
36. ′ ) oligoadenylate-antisense chimera Proc. Natl. Acad. Sci. USA. 90:1993;1300-1304
37. Park W.S., Miyano-Kurosaki N., Hayahune M., Nakajima E., Matsuzaki T., Shimada F., Takaku H. Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference. Nucleic Acids Res. 30:2002;4830-4835
38. 4+ T cells in HIV-1 infected hu-PBL-NOD-SCID mice. J. Exp. Med. 193:2001;651-659
39. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:1986;284-291
40. Sakai A., Hirabashi Y., Aizawa S., Tanaka M., Ida S., Oka S. Investigation of a new p24 antigen detection system by the chemiluminescence- enzyme-immuno-assay. J. Japn. Assoc. Infect. Dis. 73:1999;205-212
41. Reed L.J., Muench H.A. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:1938;493-497
42. Purcell D.F., Martin M.A. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J. Virol. 67:1993;6365-6378